title: Cancer classification using the Immunoscore: a worldwide task force.
abstract: Prediction of clinical outcome in cancer is usually achieved by histopathological evaluation of tissue samples obtained during surgical resection of the primary tumor. Traditional tumor staging (AJCC/UICC-TNM classification) summarizes data on tumor burden (T), presence of cancer cells in draining and regional lymph nodes (N) and evidence for metastases (M). However, it is now recognized that clinical outcome can significantly vary among patients within the same stage. The current classification provides limited prognostic information, and does not predict response to therapy. Recent literature has alluded to the importance of the host immune system in controlling tumor progression. Thus, evidence supports the notion to include immunological biomarkers, implemented as a tool for the prediction of prognosis and response to therapy. Accumulating data, collected from large cohorts of human cancers, has demonstrated the impact of immune-classification, which has a prognostic value that may add to the significance of the AJCC/UICC TNM-classification. It is therefore imperative to begin to incorporate the 'Immunoscore' into traditional classification, thus providing an essential prognostic and potentially predictive tool. Introduction of this parameter as a biomarker to classify cancers, as part of routine diagnostic and prognostic assessment of tumors, will facilitate clinical decision-making including rational stratification of patient treatment. Equally, the inherent complexity of quantitative immunohistochemistry, in conjunction with protocol variation across laboratories, analysis of different immune cell types, inconsistent region selection criteria, and variable ways to quantify immune infiltration, all underline the urgent requirement to reach assay harmonization. In an effort to promote the Immunoscore in routine clinical settings, an international task force was initiated. This review represents a follow-up of the announcement of this initiative, and of the J Transl Med. editorial from January 2012. Immunophenotyping of tumors may provide crucial novel prognostic information. The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune).
authors.affiliation: INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F-75006, France. jerome.galon@crc.jussieu.fr
authors.forename: Jérôme
authors.initials: J
authors.lastname: Galon
authors.forename: Franck
authors.initials: F
authors.lastname: Pagès
authors.forename: Francesco M
authors.initials: FM
authors.lastname: Marincola
authors.forename: Helen K
authors.initials: HK
authors.lastname: Angell
authors.forename: Magdalena
authors.initials: M
authors.lastname: Thurin
authors.forename: Alessandro
authors.initials: A
authors.lastname: Lugli
authors.forename: Inti
authors.initials: I
authors.lastname: Zlobec
authors.forename: Anne
authors.initials: A
authors.lastname: Berger
authors.forename: Carlo
authors.initials: C
authors.lastname: Bifulco
authors.forename: Gerardo
authors.initials: G
authors.lastname: Botti
authors.forename: Fabiana
authors.initials: F
authors.lastname: Tatangelo
authors.forename: Cedrik M
authors.initials: CM
authors.lastname: Britten
authors.forename: Sebastian
authors.initials: S
authors.lastname: Kreiter
authors.forename: Lotfi
authors.initials: L
authors.lastname: Chouchane
authors.forename: Paolo
authors.initials: P
authors.lastname: Delrio
authors.forename: Hartmann
authors.initials: H
authors.lastname: Arndt
authors.forename: Martin
authors.initials: M
authors.lastname: Asslaber
authors.forename: Michele
authors.initials: M
authors.lastname: Maio
authors.forename: Giuseppe V
authors.initials: GV
authors.lastname: Masucci
authors.forename: Martin
authors.initials: M
authors.lastname: Mihm
authors.forename: Fernando
authors.initials: F
authors.lastname: Vidal-Vanaclocha
authors.forename: James P
authors.initials: JP
authors.lastname: Allison
authors.forename: Sacha
authors.initials: S
authors.lastname: Gnjatic
authors.forename: Leif
authors.initials: L
authors.lastname: Hakansson
authors.forename: Christoph
authors.initials: C
authors.lastname: Huber
authors.forename: Harpreet
authors.initials: H
authors.lastname: Singh-Jasuja
authors.forename: Christian
authors.initials: C
authors.lastname: Ottensmeier
authors.forename: Heinz
authors.initials: H
authors.lastname: Zwierzina
authors.forename: Luigi
authors.initials: L
authors.lastname: Laghi
authors.forename: Fabio
authors.initials: F
authors.lastname: Grizzi
authors.forename: Pamela S
authors.initials: PS
authors.lastname: Ohashi
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Shaw
authors.forename: Blaise A
authors.initials: BA
authors.lastname: Clarke
authors.forename: Bradly G
authors.initials: BG
authors.lastname: Wouters
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kawakami
authors.forename: Shoichi
authors.initials: S
authors.lastname: Hazama
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Okuno
authors.forename: Ena
authors.initials: E
authors.lastname: Wang
authors.forename: Jill
authors.initials: J
authors.lastname: O'Donnell-Tormey
authors.forename: Christine
authors.initials: C
authors.lastname: Lagorce
authors.forename: Graham
authors.initials: G
authors.lastname: Pawelec
authors.forename: Michael I
authors.initials: MI
authors.lastname: Nishimura
authors.forename: Robert
authors.initials: R
authors.lastname: Hawkins
authors.forename: Réjean
authors.initials: R
authors.lastname: Lapointe
authors.forename: Andreas
authors.initials: A
authors.lastname: Lundqvist
authors.forename: Samir N
authors.initials: SN
authors.lastname: Khleif
authors.forename: Shuji
authors.initials: S
authors.lastname: Ogino
authors.forename: Peter
authors.initials: P
authors.lastname: Gibbs
authors.forename: Paul
authors.initials: P
authors.lastname: Waring
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Sato
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Torigoe
authors.forename: Kyogo
authors.initials: K
authors.lastname: Itoh
authors.forename: Prabhu S
authors.initials: PS
authors.lastname: Patel
authors.forename: Shilin N
authors.initials: SN
authors.lastname: Shukla
authors.forename: Richard
authors.initials: R
authors.lastname: Palmqvist
authors.forename: Iris D
authors.initials: ID
authors.lastname: Nagtegaal
authors.forename: Yili
authors.initials: Y
authors.lastname: Wang
authors.forename: Corrado
authors.initials: C
authors.lastname: D'Arrigo
authors.forename: Scott
authors.initials: S
authors.lastname: Kopetz
authors.forename: Frank A
authors.initials: FA
authors.lastname: Sinicrope
authors.forename: Giorgio
authors.initials: G
authors.lastname: Trinchieri
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Gajewski
authors.forename: Paolo A
authors.initials: PA
authors.lastname: Ascierto
authors.forename: Bernard A
authors.initials: BA
authors.lastname: Fox
mesh_terms: D026683:Advisory Committees; D002965:Classification / Q000379:methods*; D006801:Humans; D038622:Internationality; D009369:Neoplasms / Q000145:classification* / Q000276:immunology* / Q000628:therapy; D016896:Treatment Outcome; D059016:Tumor Microenvironment